Since the original descriptions more than 100 years ago,' 2 The "pure" form of HSP was first reported by Strumpell in 1880,2 who shortly afterwards also described the first neuropathological study. 6 In 1981, Harding4 rechecked this "Striimpell's disease" by analysing 22 families from the London area. This wide experience, with 56 patients examined personally, enabled her to establish consistent diagnostic criteria and to determine genetic heterogeneity in the autosomal dominant families. Harding identified two forms of dominant "pure" HSP: type I with an age of onset mostly below 35 years, and type II with onset usually over 35 years.
To date no specific biochemical or genetic marker of "pure" HSP has been found, and diagnosis should be based on clinical findings and positive family history. Most ancilliary diagnostic tests show non-specific results in "pure" HSP, and are only useful for the differential diagnosis of every new case.7 " As "pure" HSP is an infrequent disease,9 personal series are scant. Most investigations are carried out with a small number of patients and any attempt to analyse reported studies comes up against their lack of comparability if minimal diagnostic criteria do not coincide or are simply not mentioned.
In this paper we describe the genetic and clinical features of nine families with "pure" HSP. The study is part of a genetic and clinical investigation on hereditary ataxias, paraplegias and neuropathies, carried out in Cantabria, Spain, from 1974. Geographical and population data as well as epidemiological results have been detailed in previous reports.9
Patients and methods Patients Proband patients were initially evaluated at the hospital and thereafter systematic family research was carried out. All cooperative atrisk family members, parents, siblings and children of patients were visited in hospital or at home. In most of the affected members and in selected at-risk individuals, serial clinical examinations, yearly or less frequently, were performed.
Diagnostic criteria were those of Harding,4 that is, progressive spastic paraplegia with pyramidal signs in lower limbs, patients not being excluded if they had minimal ataxia in the upper limbs or distal wasting of moderate degree if symptoms had been present for more than 10 years. In this study, an asymptomatic patient was defined as an at-risk relative in whom knee and ankle hyperreflexia and extensor plantar responses were present, as verified by two independent examiners (JMP and JB).
No single cases were included here unless objective evidence of disease in at least one additional family member had been found.
In addition to the nine index patients, 109 relatives were examined of whom 37 were found to be affected. Thus a total of 46 affected members were personally examined. A further 10 living relatives were affected as a result of their history at the beginning of the study. Patients I-I and 1-2 in family E were examined in 1929 by Dr Jose M AldamaTruchuelo in the former "Casa de SaludValdecilla", and clinical data were obtained from medical records.
A three point functional grading scale, modified from Behan and Maia,'0 was adopted for the study. Grade 1 corresponds to an asymptomatic patient who had pyramidal signs in the lower limbs with normal or only slightly spastic gait; grade 2 refers to a patient with spastic gait, able to walk independently with or without support; and grade 3 if the patient was chairbound or bedridden.
Electrophysiological techniques
We concentrated here on patients in whom central motor conduction time (CMCT) was studied. Other electrophysiological features, including motor and sensory nerve conduction studies and somatosensory and brainstem auditory evoked potentials, will be published later.
Nerve conduction velocity and electromyography were performed according to the method described in an earlier study. As an approximation to genetic counselling in early-onset families, we have analysed the siblings at-risk in which all siblings were examined, divided in two groups depending on whether the examination took place before or after the age of 20 (table 2). This limit was chosen provided that mean and median age of onset in type I were between 15-20 years. The proportion of affected to unaffected cases did not differ from the expected 50%. Five of the 13 affected were asymptomatic, four of them in the younger group.
Incomplete penetrance based on history was determined in the early-onset family B, in which three apparently unaffected men had transmitted the disease. None of them could be examined as they had died at 78, 53 and 34 years, respectively, before the start of this study. But in family D, patients D-III-12 and D-III-19, two women both daughter and mother of affected and examined women, were asymptomatic and had a normal neurological examination at the ages of 52 and 53.
Although homozygosity could be invoked for members in the second generation in family E (fig 1) , none of the three affected subjects of the sibship had by history unusual clinical features that would not have been expected in heterozygotes.
AUTOSOMAL RECESSIVE FAMILIES
In two families the disease was confined to one generation ( fig 2) . In family H a man and two women were affected. Two siblings were stillborn and two others had died during the first year of life, and no further information about them was available. The father had died at the age of 80, before the start of the study, but he did not show any symptoms to suggest HSP before his death. The mother was neurologically normal when examined at the age of 81. Because the parents were first cousins and no other case was known in the family, it was thought that recessive inheritance was very likely. In family I, where three out of eight siblings were found to be affected, no other case was known among the ancestors and the parents, who were consanguineous, had a normal neurological examination at the age of 75 and 74 years.
There were three men and three women affected in both families and the onset occurred in the first decade of life in all of them Table 1 Autosomal dominant "pure" HSP: age of onset (years) G  35  10  30  15  15  10  16  63  15  60  54  18  3  23  50  18  30  22  9  20  61  15  50  18  38  18  50  14  35  42  50  45  37  Mean  46-71  19-67  43-85  24-6  14-0  6-5  19-67   Table 2 Early-onset AD "pure" HSP: persons at risk at the time of study 
Reduction of vibration sense in the feet, found in 10 patients, was the only sensation abnormality. It was more frequent in type II, but the difference was not significant. In earlyonset patients, the mean (SD) duration of disease was longer in those with sensory loss, 37 (29 93 ) years, than in those with normal sensory examination, 9-69 (14-49) years (p < 0 005). In late-onset patients the difference was not significant, 14-4 (11 08) years as opposed to 6-71 (5 22) years (p > 0 05). Joint position sense was normal in all patients as was superficial sensation. With the upper limb findings, amyotrophy, pyramidal weakness and ataxia were absent in all patients, and although myothatic hyperreflexia; was more frequent in type II (table 3), the difference was not significant. Seven patients had urinary symptoms, which consisted of permanent incontinence in one and urgent micturition in the other six. Anal control was normal in all patients. Sexual involvement was not analysed because it was not assessed in most cases.
The size of samples precludes any comparison between the presence and duration of diverse symptoms and the duration of disease if subtypes were to be considered. Two patients in type I and three in type II were chair-bound, having reached this level of severity between the ages of 50 and 75. But in the late-onset patients the duration of the disease was 9, 20 and 24 years, whereas in the early-onset it was 40 and 60. Similarly, comparison of severity between sexes was not feasible; the only remarkable difference was the higher number of asymptomatic women in type I, 9 as opposed to 3 men. Nine patients had died since the start of the study. Unfortunately post mortem examination was unavailable in any of the cases.
AUTOSOMAL RECESSIVE PATIENTS
The six patients in the recessive families experienced a gradual deterioration of the lower extremities that had stabilised after 10-20 years, but no major clinical differences were found in relation to dominant cases (table  3) . Gait disorder was severe in all, and at-resthypertonia and weakness predominated in those with a longer duration of symptoms. All had pes cavus, whereas reduction of vibratory sensation occurred only in two patients in family I. The three siblings in family H had had unmodified urinary urgency and frequency for more than 20 years. All showed asymptomatic hyperreflexia in upper limbs.
Electrophysiological studies Eight dominant patients (six men, two women) had motor conduction studies ( found 49 probable recessively inherited pedigrees among 74 published families, but it is clear that their material was clinically heterogeneous. X-linked inherited "pure" HSP is exceedingly rare5 and only one family with apparent certainty has been described. '6 Genetic heterogeneity regarding age of onset seems a well established fact in autosomal dominant "pure" HSP.4 Most of the patients in this series conform to the cut-off point at 35 years proposed by Harding.4 Schady and Sheard"7 recently found that 20 years might be a better limit to avoid overlap between early and late-onset types. This lack of concensus may in part be explained by the difficulty in establishing the precise time of onset in a disease with insidious beginning of symptoms.'8 In fact, the age at which the degenerative process becomes apparent is rarely or never the true age of onset of the disease.'5 In our early-onset dominant patients, penetrance was apparently complete before the age of 20, and therefore it seems possible to recognise the disease even when patients are still asymptomatic. Because some exceptions may occur, as this study indicates, it should be borne in mind that the absence of signs in an individual at-risk does not rule out the likelihood of becoming ill, irrespective of the age at which examination is performed. This variable expression in relation to age of onset, not uncommon in dominantly inherited disorders, may be complicated still further due to the incomplete penetrance of the gene. Such a possibility in "pure" HSP was suggested by Burdick et al,'9 based on the fact that some children became symptomatic before their parents, who later also became affected. But in the family that Burdick studied the disparity of age of onset lay on the earliness of the disease in the youngest generation, giving the impression that genetic anteposition and variable expression were perhaps confused with incomplete penetrance. In autosomal dominant disorders an incomplete penetrance occurs when a carrier of the specific gene shows no clinical sign of it,20 but is able to transmit it. Generation leaps based on family history that occurred in our family B, have occasionally been reported.'0 21-24 But the high proportion of asymptomatic patients in "pure" HSP make it risky to consider as unaffected an ancestor who has not been examined. Bickerstaff 2' and Bone et al5 reported objective instances of incomplete penetrance, but we agree with Harding5 that the clinical picture in affected descendants was, to say the least, atypical. On the other hand, we have found in an early-onset family two healthy women, descendants and mothers of examined patients. Provided that maternity is always confirmed, we conclude that, from a practical point of view, they constitute two cases of incomplete penetrance. Genetic counselling in "pure" HSP therefore sometimes becomes a difficult task. A specific genetic marker is a pressing need.
Apart from the variability in age of onset, the clinical features of "pure" HSP are quite stereotyped.4 But some aspects deserve comment. We were surprised by the high number of asymptomatic, but clinically affected, patients when a systematic study of the families was carried out. Already present in earlier descriptions,26 the existence of asymptomatic patients in "pure" HSP was specifically mentioned by Bickerstaff2" and Ozsvath.27 Harding4 found that 23% of her early-onset dominant patients were asymptomatic; intriguingly, in our series there were some even in late-onset families.
The inclusion of those probable affected28 as affected cases implies the risk of an exaggerated diagnostic enthusiasm,2 1 but serial examinations eventually lead to an unequivocal diagnosis. We come to the conclusion that myotatic hyperreflexia and extensor plantar responses, if consistenly assessed, are enough to assure the presence of the gene in an at-risk person. This fact also emphasises the need and usefulness of examining the greatest number of individuals in every new family.
Once started, the gait disorder increases slowly to a variable severity level. There is a characteristic predominance of dynamic spasticity over pyramidal weakness and at-rest hypertonia. This spasmodic pseudoparalysis, already recognised in early studies,2 is associated with flexor plantar responses in some patients with an important handicap. Appel3 interpreted this particular combination of signs as the result of an area 6 syndrome, an attractive hypothesis not demonstrated for the moment. As occurred in six -patients of our series, flexor plantar responses have been reported in some patients with an otherwise definite clinical picture;' 23 29-31 this fact militates against including Babinski's sign as an obligatory criterion of the disease. 8 In spite of the fact that degeneration of the Goll columns is a constant pathological finding in "pure" HSP,'°only a quarter of our patients showed involvement of propioceptive sensation, a proportion which coincides with that found by Harding.4 Such clinico-pathological -dissociation has also been described in olivopontocerebellar atrophy.32 In "pure" HSP it characteristically consists of a loss of vibratory perception in the legs and feet with an almost always normal position sense, and is usually a late clinical feature.
A more or less marked pes cavus was a sign present in more than half of the patients, and in dominant families it was more frequent in those with an earlier onset. It has been stated that foot deformity in HSP may be different from other neurological conditions in that the arching disappears on standing.2' 33 Most of the patients in this series had slight deformities, but if pronounced it was indistinguishable from that found in other spinocerebellar syndromes. Incidentally, one patient had pes planus.2934 Late involvement of the upper limbs has been considered as an infrequent but characteristic feature in "pure" HSP.4 10 Increased upper limb reflexes may be present, as in a third of our patients, even in the early stages.24 But none of them had pyramidal weakness and in Harding's series4 only two patients showed symptoms in the upper limbs. Even though pyramidal signs can be detected in some, it therefore seems clear that brachial manifestations are exceptional. Philip35 reported for the first time urinary symptoms in "pure" HSP. Although these symptoms had been considered infrequent,36 nearly half of the patients in Harding's series4 had urinary urgency or urinary frequency. In our series 10 patients had impaired urinary function, generally as a late clinical feature. 4 The impression, mentioned by Bickerstaff, 2' that the earlier the onset the faster its evolu- CMCT in "pure" HSP is increased in a proportion of patients, central motor conduction studies lack value in detecting subclinical lesions in most patients with HSP. 7 The term "pure" when applied to "pure" HSP is more than semantic because it refers to a clinical reality. As 
